Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08HFW
|
|||
Former ID |
DCL000657
|
|||
Drug Name |
TAK-901
|
|||
Synonyms |
TAK-901; 934541-31-8; TAK901; TAK 901; UNII-DM9UIR23R7; 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; DM9UIR23R7; 5-[3-(Ethylsulfonyl)phenyl]-3,8-dimethyl-N-(1-methyl-4-piperidinyl)-9H-pyrido[2,3-b]indole-7-carboxamide; C28H32N4O3S; 5-[3-(ethanesulfonyl)phenyl]-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; 5-(3-ethylsulfonylphenyl)-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide; cc-11; MLS006010174
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Haematological malignancy [ICD-11: 2B33.Y] | Phase 1 | [1] | |
Company |
Takeda
|
|||
Structure |
Download2D MOL |
|||
Formula |
C28H32N4O3S
|
|||
Canonical SMILES |
CCS(=O)(=O)C1=CC=CC(=C1)C2=CC(=C(C3=C2C4=C(N3)N=CC(=C4)C)C)C(=O)NC5CCN(CC5)C
|
|||
InChI |
1S/C28H32N4O3S/c1-5-36(34,35)21-8-6-7-19(14-21)23-15-22(28(33)30-20-9-11-32(4)12-10-20)18(3)26-25(23)24-13-17(2)16-29-27(24)31-26/h6-8,13-16,20H,5,9-12H2,1-4H3,(H,29,31)(H,30,33)
|
|||
InChIKey |
WKDACQVEJIVHMZ-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 934541-31-8
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
24772915, 28725871, 40658123, 124976958, 131549293, 136340315, 136349569, 136367700, 139700564, 152258406, 160647243, 162011362, 162038103, 162202640, 164020967, 164194000, 172914487, 174006378, 174531561, 185979181, 202559448, 223388595, 223704783, 224282669, 226944802, 242060029, 249254536, 251910775, 252109875, 252165326, 252216369
|
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029358) | |||
REF 2 | Clinical pipeline report, company report or official report of Takeda (2009). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.